{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SJIA",
    "query": {
      "condition": "SJIA"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 21,
    "total_pages": 3,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=SJIA&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T16:01:53.795Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00889863",
      "title": "Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis With Active Flare"
      ],
      "interventions": [
        {
          "name": "canakinumab",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 177,
      "start_date": "2009-07",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2012-10-16",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 12,
      "location_summary": "Little Rock, Arkansas • Washington D.C., District of Columbia • Chicago, Illinois + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00889863"
    },
    {
      "nct_id": "NCT07203001",
      "title": "A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Still´s Disease"
      ],
      "interventions": [
        {
          "name": "MAS825",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "1 Year to 100 Years"
      },
      "enrollment_count": 30,
      "start_date": "2025-11-03",
      "completion_date": "2028-05-17",
      "has_results": false,
      "last_update_posted_date": "2026-07-10",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Portland, Oregon",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07203001"
    },
    {
      "nct_id": "NCT03000439",
      "title": "A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Arthritis Juvenile Idiopathic"
      ],
      "interventions": [
        {
          "name": "In open-label phase: treatment with tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "2 Years to 17 Years"
      },
      "enrollment_count": 100,
      "start_date": "2018-05-10",
      "completion_date": "2024-03-27",
      "has_results": true,
      "last_update_posted_date": "2025-06-03",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New Hyde Park",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03000439"
    },
    {
      "nct_id": "NCT00886769",
      "title": "Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Canakinumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "2 Years to 19 Years"
      },
      "enrollment_count": 84,
      "start_date": "2009-07",
      "completion_date": "2011-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-29",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 15,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00886769"
    },
    {
      "nct_id": "NCT00534495",
      "title": "Safety and Effectiveness of Rilonacept for Treating Systemic Juvenile Idiopathic Arthritis in Children and Young Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Rilonacept",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Montefiore Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "19 Years",
        "sex": "ALL",
        "summary": "18 Months to 19 Years"
      },
      "enrollment_count": 71,
      "start_date": "2008-11",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2015-12-11",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00534495"
    },
    {
      "nct_id": "NCT05609630",
      "title": "Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 90,
      "start_date": "2023-10-02",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-07-21",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Washington D.C., District of Columbia • Valhalla, New York + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Valhalla",
          "state": "New York"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609630"
    },
    {
      "nct_id": "NCT02296424",
      "title": "ß-SPECIFIC 4 Patients: Study of Pediatric EffiCacy and Safety wIth FIrst-line Use of Canakinumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Systemic Juvenile Idiopathic Arthritis (SJIA)"
      ],
      "interventions": [
        {
          "name": "ACZ885 150 mg (Canakinumab)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "2 Years to 20 Years"
      },
      "enrollment_count": 182,
      "start_date": "2014-11-17",
      "completion_date": "2017-09-25",
      "has_results": true,
      "last_update_posted_date": "2019-07-09",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Columbus, Ohio",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02296424"
    },
    {
      "nct_id": "NCT00868751",
      "title": "Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Arthritis, Juvenile Rheumatoid",
        "Still's Disease, Juvenile Onset"
      ],
      "interventions": [
        {
          "name": "tocilizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Tufts Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "2 Years to 16 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-03",
      "completion_date": "2010-06",
      "has_results": true,
      "last_update_posted_date": "2017-05-15",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00868751"
    },
    {
      "nct_id": "NCT01962415",
      "title": "Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Immunodeficiency (PID)",
        "Congenital Bone Marrow Failure Syndromes",
        "Inherited Metabolic Disorders (IMD)",
        "Hereditary Anemias",
        "Inflammatory Conditions",
        "Systemic Juvenile Idiopathic Arthritis (sJIA)",
        "Juvenile Rheumatoid Arthritis (JRA)"
      ],
      "interventions": [
        {
          "name": "Hydroxyurea",
          "type": "DRUG"
        },
        {
          "name": "Alemtuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Thiotepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Paul Szabolcs",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "2 Months to 55 Years"
      },
      "enrollment_count": 100,
      "start_date": "2014-02-04",
      "completion_date": "2027-11",
      "has_results": false,
      "last_update_posted_date": "2025-12-15",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01962415"
    },
    {
      "nct_id": "NCT02165345",
      "title": "Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Juvenile Idiopathic Arthritis"
      ],
      "interventions": [
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 82,
      "start_date": "2014-07-16",
      "completion_date": "2021-11-24",
      "has_results": false,
      "last_update_posted_date": "2022-02-23",
      "last_synced_at": "2026-07-22T16:01:53.795Z",
      "location_count": 9,
      "location_summary": "Little Rock, Arkansas • Chicago, Illinois • Hackensack, New Jersey + 6 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165345"
    }
  ]
}